203 related articles for article (PubMed ID: 32747470)
1. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
Young AC; Quach HT; Song H; Davis EJ; Moslehi JJ; Ye F; Williams GR; Johnson DB
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32747470
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy.
Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W
Front Immunol; 2023; 14():1261202. PubMed ID: 38077332
[TBL] [Abstract][Full Text] [Related]
3. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
[TBL] [Abstract][Full Text] [Related]
4. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
5. Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
Xiao LS; Li RN; Cui H; Hong C; Huang CY; Li QM; Hu CY; Dong ZY; Zhu HB; Liu L
BMC Cancer; 2022 Jul; 22(1):737. PubMed ID: 35794525
[TBL] [Abstract][Full Text] [Related]
6. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
7. Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study.
Wang J; Dong P; Qu Y; Xu W; Zhou Z; Ning K; Peng Y; Xiong L; Li Z; Zou X; Liu Z; Li M; He Z; Luo J; Tian X; Zhang H; Guo S; Han H; Zhou F; Yin S; Ye D; Yu C; Zhang Z
Eur Radiol; 2023 May; 33(5):3232-3242. PubMed ID: 36538073
[TBL] [Abstract][Full Text] [Related]
8. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
9. Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma.
Chu MP; Li Y; Ghosh S; Sass S; Smylie M; Walker J; Sawyer MB
J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):748-755. PubMed ID: 32053287
[TBL] [Abstract][Full Text] [Related]
10. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.
Rutkowski P; Indini A; De Luca M; Merelli B; Mariuk-Jarema A; Teterycz P; Rogala P; Lugowska I; Cybulska-Stopa B; Labianca A; Di Guardo L; Del Vecchio M; Pigozzo J; Randon G; Corti F; Tondini CA; Rulli E; Mandala M
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203662
[TBL] [Abstract][Full Text] [Related]
11. Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer.
Shachar SS; Deal AM; Weinberg M; Williams GR; Nyrop KA; Popuri K; Choi SK; Muss HB
Clin Cancer Res; 2017 Jul; 23(14):3537-3543. PubMed ID: 28143874
[No Abstract] [Full Text] [Related]
12. Subcutaneous Fat Abundance and Density Are Associated with an Enhanced Response to Immunotherapy in Metastatic Melanoma: A Retrospective Cohort Study.
Mengoni M; Braun AD; Hinnerichs MS; Tüting T; Surov A
Acad Radiol; 2023 Sep; 30 Suppl 1():S257-S267. PubMed ID: 37331867
[TBL] [Abstract][Full Text] [Related]
13. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Naik GS; Waikar SS; Johnson AEW; Buchbinder EI; Haq R; Hodi FS; Schoenfeld JD; Ott PA
J Immunother Cancer; 2019 Mar; 7(1):89. PubMed ID: 30922394
[TBL] [Abstract][Full Text] [Related]
14. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
[TBL] [Abstract][Full Text] [Related]
16. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
17. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
18. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
19. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
